Michael C Burns

3PUBLICATIONS
32CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

|May 01, 2026
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.

|Mar 30, 2026
Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met-Targeting Antibody-Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer.

John H Strickler, Judith Raimbourg, Jonathan E Cohen

|Jan 09, 2021
Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2-ERG fusions.

Zachary R Chalmers, Michael C Burns, Ericka M Ebot

Pageof 1

Frequent Collaborators

2 joint publications

John H Strickler

2 joint publications

Yasutoshi Kuboki

2 joint publications

Jonathan E Cohen

2 joint publications

Manish R Sharma